(MOPETT) Trial

ePAPER READ

DOWNLOAD ePAPER

cardio.se

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

START NOW

Primary Endpoints

Pulmonary HTN at 28 m

Pulmonary HTN +

recurrent PE at 28 m

TG N=

58

CG N=56

p Value

9 (16) 32 (57) p

Management of patients with palpitations: a position paper from the ...

Hela numret kan lÃ¤sas hÃ¤r. - Svenska CardiologfÃ¶reningen

LÃ¤s hela numret. - Svenska CardiologfÃ¶reningen

Kateterablation vid ventrikulÃ¤ra arrytmier

HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)

CHAMPION PHOENIX Presentation Slides.pptx

Svensk Cardiologi 3 2010 - Svenska CardiologfÃ¶reningen

Svensk Cardiologi 4 2012 - Svenska CardiologfÃ¶reningen

Primary Endpoints Pulmonary HTN at 28 m Pulmonary HTN + recurrent PE at 28 m TG N= 58 CG N=56 p Value 9 (16) 32 (57) p

Secondary Endpoints TG N= 61 CG N=60 p Value Recurrent PE 0 3 (5) 0.077 Mortality 1(1.6) 3 (5) 0.301 PE + Mortality 1 (1.6) 6 (10) 0.0489 Hospital Stay 2.2±0.5 4.9±0.8

Page 1 and 2: Moderate Pulmonary Embolism Treated
Page 3 and 4: Pulmonary Embolism • >100,000 ann
Page 5 and 6: • Standard dose t-PA 100mg in 2 h
Page 7 and 8: “ SAFER DOSE t-PA”
Page 17 and 18: MOPETT Trial 121 Patients TT= 61 CG
Page 19 and 20: Secondary Endpoints • In-Hospital
Page 21 and 22: Evaluation of Troponin I and BNP Ec
Page 23 and 24: “Safe Dose” t-PA • For ≥ 50
Page 25: Concomitant Anticoagulation TG •
Page 29 and 30: Anticoagulation CG • Enoxaparin (
Page 31: TG CG p Value Initial PASPmm Hg 50
Page 35: Changes in PASP ( mmHg )
Page 38: HAPPY NOWRUZ

(MOPETT) Trial

Create successful ePaper yourself

Delete template?

Save as template?